Origins of resistance to the HIVgp41 viral entry inhibitor T20

Biochemistry

Volumn 49, Issue 17, 2010, Pages 3575-3592

  McGillick, Brian E ^a   Balius, Trent E ^b   Mukherjee, Sudipto ^b   Rizzo, Robert C ^b  

^a Stony Brook University   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMIC LEVELS; BINDING ENERGY ANALYSIS; BOND INTERACTIONS; CLINICAL USE; DRUG RESISTANCE; ENERGY DECOMPOSITION; FAVORABLE INTERACTIONS; FOOTPRINTING; FUSION PEPTIDES; HEAD GROUPS; INTERMOLECULAR H-BONDING; MAP ANALYSIS; MEMBRANE FUSION; MOLECULAR DYNAMICS SIMULATIONS; POINT MUTATIONS; QUANTITATIVE AGREEMENT; SIDE CHAINS; STABLE COMPLEXES; VAN DER WAALS; VAN DER WAALS INTERACTIONS; WILD TYPES;

CELL MEMBRANES; COMPUTER SIMULATION; ENERGY MANAGEMENT; MOLECULAR DYNAMICS; PEPTIDES; VAN DER WAALS FORCES; VIRUSES;

BINDING ENERGY;

ENFUVIRTIDE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CLINICAL ASSESSMENT; COMPUTER SIMULATION; DRUG BINDING; DRUG PROTEIN BINDING; ENERGY TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS; HYDROGEN BOND; MEMBRANE FUSION; MOLECULAR DYNAMICS; MUTANT; POINT MUTATION; PRIORITY JOURNAL; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; VIRUS ENTRY;

AMINO ACID SEQUENCE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; SEQUENCE HOMOLOGY, AMINO ACID; VIRUS INTERNALIZATION;

EID: 77951670043     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi901915g     Document Type: Article

References (77)

1. -2008 Report on the global AIDS epidemic: Epidemiology slides, Joint United Nations Programme on HIV/AIDS (UNAIDS) and The World Health Organization (WHO). http://data.unaids.org/pub/GlobalReport/2008/2008-globalreport-core-en. ppt (accessed August 3, 2009).
2. NIGMS-Supported Structure-Based Drug Design Saves Lives, NIH/NIGMS Fact Sheet. http://www.nigms.nih.gov/Publications/structure-drugs.htm (accessed August 3, 2009).
3. Drugs@FDA website. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm (accessed August 3, 2009).
4. Grinsztejn, B., Nguyen, B. Y., Katlama, C., Gatell, J. M., Lazzarin, A., Vittecoq, D., Gonzalez, C. J., Chen, J., Harvey, C. M., and Isaacs, R. D. (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial Lancet 369, 1261-1269
5. Davison, D. K., Medinas, R. J., Mosier, S. M., Bowling, T. S., Delmedico, M. K., Dwyer, J. J., Cammack, N., and Greenberg, M. L. (2006) New fusion inhibitor peptides, TRI-999 and TRI-1144, are potent inhibitors of enfuvirtide and T-1249 resistant isolates. XVI International AIDS Conference: Conference Reports for NATAP, Poster THPE0021.
6. Eckert, D. M. and Kim, P. S. (2001) Mechanisms of viral membrane fusion and its inhibition Annu. Rev. Biochem. 70, 777-810
7. Suntoke, T. R. and Chan, D. C. (2005) The Fusion Activity of HIV-1 gp41 Depends on Interhelical Interactions J. Biol. Chem. 280, 19852-19857
8. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from the HIV envelope glycoprotein Cell 89, 263-273
9. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. (1997) Atomic structure of the ectodomain from HIV-1 gp41 Nature 387, 426-430
10. Schibli, D. J. and Weissenhorn, W. (2004) Class I and class II viral fusion protein structures reveal similar principles in membrane fusion Mol. Membr. Biol. 21, 361-371
11. Eckert, D. M. and Kim, P. S. (2001) Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region Proc. Natl. Acad. Sci. U.S.A. 98, 11187-11192
12. Jiang, S. B., Lin, K., Strick, N., and Neurath, A. R. (1993) Hiv-1 Inhibition by a Peptide Nature 365, 113
13. Wild, C., Oas, T., McDanal, C., Bolognesi, D., and Matthews, T. (1992) A Synthetic Peptide Inhibitor of Human Immunodeficiency Virus Replication: Correlation between Solution Structure and Viral Inhibition Proc. Natl. Acad. Sci. U.S.A. 89, 10537-10541
14. Eckert, D. M., Malashkevich, V. N., Hong, L. H., Carr, P. A., and Kim, P. S. (1999) Inhibiting HIV-1 entry: Discovery of d -peptide inhibitors that target the gp41 coiled-coil pocket Cell 99, 103-115
15. Welch, B. D., VanDemark, A. P., Heroux, A., Hill, C. P., and Kay, M. S. (2007) Potent d -peptide inhibitors of HIV-1 entry Proc. Natl. Acad. Sci. U.S.A. 104, 16828-16833
16. Chan, D. C., Chutkowski, C. T., and Kim, P. S. (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target Proc. Natl. Acad. Sci. U.S.A. 95, 15613-15617
17. Debnath, A. K., Radigan, L., and Jiang, S. B. (1999) Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1 J. Med. Chem. 42, 3203-3209
18. Jiang, S. B., Lu, H., Liu, S. W., Zhao, Q., He, Y. X., and Debnath, A. K. (2004) N-Substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion Antimicrob. Agents Chemother. 48, 4349-4359
19. Frey, G., Rits-Volloch, S., Zhang, X. Q., Schooley, R. T., Chen, B., and Harrison, S. C. (2006) Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion Proc. Natl. Acad. Sci. U.S.A. 103, 13938-13943
20. Cai, L. and Gochin, M. (2007) A Novel Fluorescence Intensity Screening Assay Identifies New Low Molecular Weight Inhibitors of the gp41 Coiled Coil Domain of HIV-1 Antimicrob. Agents Chemother. 51, 2388-2395
21. nd Generation Fusion Inhibitors and Cytopathic in ex vivo Human Lymphoid Tissue J. Virol. DOI: 10.1128/JVI.02546-06 (Pubitemid 46878060)
22. Armand-Ugon, M., Gutierrez, A., Clotet, B., and Este, J. A. (2003) HIV-1 resistance to the gp41-dependent fusion inhibitor C-34 Antiviral Res. 59, 137-142
23. Armand-Ugon, M., Clotet-Codina, I., Tintori, C., Manetti, F., Clotet, B., Botta, M., and Este, J. A. (2005) The anti-HIV activity of ADS-J1 targets the HIV-1 gp120 Virology 343, 141-149
24. Greenberg, M. L. and Cammack, N. (2004) Resistance to enfuvirtide, the first HIV fusion inhibitor J. Antimicrob. Chemother. 54, 333-340
25. Mink, M., Mosier, S. M., Janumpalli, S., Davison, D., Jin, L., Melby, T., Sista, P., Erickson, J., Lambert, D., Stanfield-Oakley, S. A., Salgo, M., Cammack, N., Matthews, T., and Greenberg, M. L. (2005) Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro J. Virol. 79, 12447-12454
26. Melby, T., Sista, P., DeMasi, R., Kirkland, T., Roberts, N., Salgo, M., Heilek-Snyder, G., Cammack, N., Matthews, T. J., and Greenberg, M. L. (2006) Characterization of Envelope Glycoprotein gp41 Genotype and Phenotypic Susceptibility to Enfuvirtide at Baseline and on Treatment in the Phase III Clinical Trials TORO-1 and TORO-2 AIDS Res. Hum. Retroviruses 22, 375-385
27. Nameki, D., Kodama, E., Ikeuchi, M., Mabuchi, N., Otaka, A., Tamamura, H., Ohno, M., Fujii, N., and Matsuoka, M. (2005) Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp4l and rev-responsive element functions J. Virol. 79, 764-770
28. Rimsky, L. T., Shugars, D. C., and Matthews, T. J. (1998) Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides J. Virol. 72, 986-993
29. Strockbine, B. and Rizzo, R. C. (2007) Binding of Anti-fusion Peptides with HIVgp41 from Molecular Dynamics Simulations: Quantitative Correlation with Experiment Proteins: Struct., Funct., Bioinf. 63, 630-642
30. Caffrey, M. (2001) Model for the structure of the HIV gp41 ectodomain: Insight into the intermolecular interactions of the gp41 loop Biochim. Biophys. Acta 1536, 116-122
31. Lori, F., Hall, L., Lusso, P., Popovic, M., Markham, P., Franchini, G., and Reitz, M. S., Jr. (1992) Effect of reciprocal complementation of two defective human immunodeficiency virus type 1 (HIV-1) molecular clones on HIV-1 cell tropism and virulence J. Virol. 66, 5553-5560
32. MOE, version 2005.06 (2005) Chemical Computing Group Inc., Montreal.
33. Case, D. A., Cheatham, T. E., III, Darden, T., Gohlke, H., Luo, R., Merz, K. M., Jr., Onufriev, A., Simmerling, C., Wang, B., and Woods, R. J. (2005) The Amber biomolecular simulation programs J. Comput. Chem. 26, 1668-1688
34. Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., and Simmerling, C. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins 65, 712-725
35. Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kale, L., and Schulten, K. (2005) Scalable molecular dynamics with NAMD J. Comput. Chem. 26, 1781-1802
36. Humphrey, W., Dalke, A., and Schulten, K. (1996) VMD: Visual molecular dynamics J. Mol. Graphics 14, 33
37. MacKerell, A. D., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., Joseph-McCarthy, D., Kuchnir, L., Kuczera, K., Lau, F. T. K., Mattos, C., Michnick, S., Ngo, T., Nguyen, D. T., Prodhom, B., Reiher, W. E., Roux, B., Schlenkrich, M., Smith, J. C., Stote, R., Straub, J., Watanabe, M., Wiorkiewicz-Kuczera, J., Yin, D., and Karplus, M. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins J. Phys. Chem. B 102, 3586-3616
38. Feller, S. E. and MacKerell, A. D. (2000) An improved empirical potential energy function for molecular simulations of phospholipids J. Phys. Chem. B 104, 7510-7515
39. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., and Klein, M. L. (1983) Comparison of Simple Potential Functions for Simulating Liquid Water J. Chem. Phys. 79, 926-935
40. Feller, S. E. Wabash College Chemistry Department. http://persweb.wabash. edu/facstaff/fellers (accessed December 22, 2008).
41. Darden, T., York, D., and Pedersen, L. (1993) Particle mesh Ewald: An Nlog(N) method for Ewald sums in large systems J. Chem. Phys. 98, 10089-10092
42. Feller, S. E., Zhang, Y., Pastor, R. W., and Brooks, B. R. (1995) Constant pressure molecular dynamics simulation: The Langevin piston method J. Chem. Phys. 103, 4613-4621
43. Ryckaert, J. P., Ciccotti, G., and Berendsen, H. J. C. (1977) Numerical-Integration of Cartesian Equations of Motion of a System with Constraints: Molecular-Dynamics of N-Alkanes J. Comput. Phys. 23, 327-341
44. Srinivasan, J., Cheatham, T. E., Cieplak, P., Kollman, P. A., and Case, D. A. (1998) Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices J. Am. Chem. Soc. 120, 9401-9409 (Pubitemid 28452628)
45. Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee, M., Lee, T., Duan, Y., Wang, W., Donini, O., Cieplak, P., Srinivasan, J., Case, D. A., and Cheatham, T. E. (2000) Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models Acc. Chem. Res. 33, 889-897
46. Balius, T. E. and Rizzo, R. C. (2009) Quantitative Prediction of Fold Resistance for Inhibitors of EGFR Biochemistry 48, 8435-8448
47. Carrascal, N. and Rizzo, R. C. (2009) Calculation of binding free energies for non-zinc chelating pyrimidine dicarboxamide inhibitors with MMP-13 Bioorg. Med. Chem. Lett. 19, 47-50
48. Chachra, R. and Rizzo, R. C. (2008) Origins of Resistance Conferred by the R292K Neuraminidase Mutation via Molecular Dynamics and Free Energy Calculations J. Chem. Theory Comput. 4, 1526-1540
49. Hawkins, G. D., Cramer, C. J., and Truhlar, D. G. (1995) Pairwise Solute Descreening of Solute Charges from a Dielectric Medium Chem. Phys. Lett. 246, 122-129
50. Hawkins, G. D., Cramer, C. J., and Truhlar, D. G. (1996) Parametrized models of aqueous free energies of solvation based on pairwise descreening of solute atomic charges from a dielectric medium J. Phys. Chem. 100, 19824-19839
51. Moustakas, D. T., Therese Lang, P. T., Pegg, S., Pettersen, E., Kuntz, I. D., Broojimans, N., and Rizzo, R. C. (2006) Development and Validation of a Modular, Extensible Docking program: DOCK 5 J. Comput.-Aided Mol. Des. 20, 601-619
52. Sitkoff, D., Sharp, K. A., and Honig, B. (1994) Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models J. Phys. Chem. 98, 1978-1988
53. Sackett, K., Wexler-Cohen, Y., and Shai, Y. (2006) Characterization of the HIV N-terminal fusion peptide-containing region in context of key gp41 fusion conformations J. Biol. Chem. 281, 21755-21762
54. Kamath, S. and Wong, T. C. (2002) Membrane structure of the human immunodeficiency virus gp41 fusion domain by molecular dynamics simulation Biophys. J. 83, 135-143
55. Gordon, L. M., Mobley, P. W., Pilpa, R., Sherman, M. A., and Waring, A. J. (2002) Conformational mapping of the N-terminal peptide of HIV-1 gp41 in membrane environments using C-13-enhanced Fourier transform infrared spectroscopy Biochim. Biophys. Acta 1559, 96-120
56. Gordon, L. M., Mobley, P. W., Lee, W., Eskandari, S., Kaznessis, Y. N., Sherman, M. A., and Waring, A. J. (2004) Conformational mapping of the N-terminal peptide of HIV-1 gp41 in lipid detergent and aqueous environments using C-13-enhanced Fourier transform infrared spectroscopy Protein Sci. 13, 1012-1030
57. Sackett, K. and Shai, Y. (2005) The HIV fusion peptide adopts intermolecular parallel β-sheet structure in membranes when stabilized by the adjacent N-terminal heptad repeat: A C-13 FTIR study J. Mol. Biol. 350, 790-805
58. Zheng, Z., Yang, R., Bodner, M. L., and Weliky, D. P. (2006) Conformational flexibility and strand arrangements of the membrane-associated HIV fusion peptide trimer probed by solid-state NMR spectroscopy Biochemistry 45, 12960-12975
59. Li, Y. and Tamm, L. K. (2007) Structure and plasticity of the human immunodeficiency virus gp41 fusion domain in lipid micelles and bilayers Biophys. J. 93, 876-885
60. Yau, W. M., Wimley, W. C., Gawrisch, K., and White, S. H. (1998) The preference of tryptophan for membrane interfaces Biochemistry 37, 14713-14718
61. Scarlata, S. and Gruner, S. M. (1997) Role of phosphatidylethanolamine lipids in the stabilization of protein-lipid contacts Biophys. Chem. 67, 269-279
62. Grossfield, A., Zuckerman, D. M., and Ralph, A. W. (2009) Quantifying Uncertainty and Sampling Quality in Biomolecular Simulations. In Annual Reports in Computational Chemistry, Vol. 5, pp 23-48, Elsevier, Amsterdam.
63. Hess, B. (2002) Determining the shear viscosity of model liquids from molecular dynamics simulations J. Chem. Phys. 116, 209-217
64. Massova, I. and Kollman, P. A. (2000) Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding Perspect. Drug Discovery Des. 18, 113-135
65. Dwyer, J. J., Wilson, K. L., Davison, D. K., Freel, S. A., Seedorff, J. E., Wring, S. A., Tvermoes, N. A., Matthews, T. J., Greenberg, M. L., and Delmedico, M. K. (2007) Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus Proc. Natl. Acad. Sci. U.S.A. 104, 12772-12777
66. Lu, M., Blacklow, S. C., and Kim, P. S. (1995) A trimeric structural domain of the HIV-1 transmembrane glycoprotein Nat. Struct. Biol. 2, 1075-1082
67. Eggink, D., Langedijk, J. P., Bonvin, A. M., Deng, Y., Lu, M., Berkhout, B., and Sanders, R. W. (2009) Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors J. Biol. Chem. 284, 26941-26950
68. Gochin, M. and Cai, L. (2009) The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket J. Med. Chem. 52, 4338-4344
69. Lawless, M. K., Barney, S., Guthrie, K. I., Bucy, T. B., Petteway, S. R., Jr., and Merutka, G. (1996) HIV-1 membrane fusion mechanism: Structural studies of the interactions between biologically-active peptides from gp41 Biochemistry 35, 13697-13708
70. Hildinger, M., Dittmar, M. T., Schult-Dietrich, P., Fehse, B., Schnierle, B. S., Thaler, S., Stiegler, G., Welker, R., and von Laer, D. (2001) Membrane-anchored peptide inhibits human immunodeficiency virus entry J. Virol. 75, 3038-3042
71. Peisajovich, S. G., Gallo, S. A., Blumenthal, R., and Shai, Y. (2003) C-Terminal octylation rescues an inactive T20 mutant: Implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion J. Biol. Chem. 278, 21012-21017
72. Wexler-Cohen, Y., Johnson, B. T., Puri, A., Blumenthal, R., and Shai, Y. (2006) Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178 J. Biol. Chem. 281, 9005-9010
73. Liu, S., Jing, W., Cheung, B., Lu, H., Sun, J., Yan, X., Niu, J., Farmar, J., Wu, S., and Jiang, S. (2007) HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides J. Biol. Chem. 282, 9612-9620
74. Champagne, K., Shishido, A., and Root, M. J. (2009) Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil J. Biol. Chem. 284, 3619-3627
75. Izumi, K., Kodama, E., Shimura, K., Sakagami, Y., Watanabe, K., Ito, S., Watabe, T., Terakawa, Y., Nishikawa, H., Sarafianos, S. G., Kitaura, K., Oishi, S., Fujii, N., and Matsuoka, M. (2009) Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20 J. Biol. Chem. 284, 4914-4920
76. Watabe, T., Terakawa, Y., Watanabe, K., Ohno, H., Nakano, H., Nakatsu, T., Kato, H., Izumi, K., Kodama, E., Matsuoka, M., Kitaura, K., Oishi, S., and Fujii, N. (2009) X-ray crystallographic study of an HIV-1 fusion inhibitor with the gp41 S138A substitution J. Mol. Biol. 392, 657-665
77. Qiang, W. and Weliky, D. P. (2009) HIV fusion peptide and its cross-linked oligomers: Efficient syntheses, significance of the trimer in fusion activity, correlation of β strand conformation with membrane cholesterol, and proximity to lipid headgroups Biochemistry 48, 289-301